Gl. Denardo et al., BODY AND BLOOD CLEARANCE AND MARROW RADIATION-DOSE OF I-131 LYM-1 IN PATIENTS WITH B-CELL MALIGNANCIES, Nuclear medicine communications, 14(7), 1993, pp. 587-595
Fifty-eight per cent of patients with B-cell malignancies had durable
responses to treatment with I-131-Lym-1. Myelosuppression manifested b
y peripheral blood cytopenia was the radiation dose-limiting toxicity.
The mean biologic half-times were 3.3 and 31.2 h for the fast and slo
w phases, respectively, of the blood clearance and 33.5 h for the clea
rance from the total body. Nonpenetrating radiation from the blood con
tributed 0.18 rad and penetrating radiations from the total body contr
ibuted 0.18 rad per administered mCi to the bone marrow. The average t
otal contribution from both of these sources was 0.36 +/- 0.14 rad mCi
-1. Clearances and marrow radiation doses were remarkably constant amo
ng different patients and among different therapy doses for the same p
atient. These results are potentially useful as an initial approximati
on for other mouse monoclonal antibodies of the same isotype. While ra
diation to normal marrow from 'spill-over' incident to specific target
ing of I-131-Lym-1 on malignant B-cells in the marrow is not addressed
in this publication because it is unique for each patient, it should
be considered in the case of individual patients.